Which statement describes a packaging requirement for sodium valproate?

Which statement describes a packaging requirement for sodium valproate?

• A. Under no circumstances should women or girls take sodium valproate
• B. Sodium Valproate must be supplied with a warning label on the packaging
• C. Sodium Valproate must be dispensed in Whole packs
• D. Sodium Valproate must be prescribed by a pharmacist

Answer: (B)

Sodium valproate is known to be highly teratogenic, causing birth defects and neurodevelopmental problems if taken during pregnancy. Because of this, safety rules require packaging to carry a warning that alerts patients and healthcare professionals to the risks and to prompt appropriate precautions, such as pregnancy prevention discussions and monitoring. That makes the packaging warning label the correct packaging requirement. The other statements aren’t accurate. It’s not absolute that women or girls should never take the drug—use is controlled under strict safeguards rather than completely prohibited. Packaging does not require dispensing only in whole packs. And pharmacists do not generally prescribe medications; prescribing is handled by a clinician, while pharmacists dispense.

Sodium valproate is known to be highly teratogenic, causing birth defects and neurodevelopmental problems if taken during pregnancy. Because of this, safety rules require packaging to carry a warning that alerts patients and healthcare professionals to the risks and to prompt appropriate precautions, such as pregnancy prevention discussions and monitoring. That makes the packaging warning label the correct packaging requirement.

The other statements aren’t accurate. It’s not absolute that women or girls should never take the drug—use is controlled under strict safeguards rather than completely prohibited. Packaging does not require dispensing only in whole packs. And pharmacists do not generally prescribe medications; prescribing is handled by a clinician, while pharmacists dispense.